Home › Funds › Vanguard Group › ABT
Vanguard Group position in ABT
ABBOTT LABORATORIES · Health Care
Vanguard Group reported holding 175,556,716 shares of ABT (ABBOTT LABORATORIES) in its Q4 2025 13F filing — a position valued at US$22.00B, representing 0.32% of its reported portfolio and ranking #44 among its reported holdings. Vanguard Group has disclosed ABT holdings in 20 of the last 20 reported quarters, going back to Q1 2021.
Last updated: 2026-10-05 · Source: SEC EDGAR Form 13F-HR
How Vanguard Group's ABT position evolved
Vanguard Group first disclosed a stake in ABT in Q1 2021 at 146,567,914 shares (US$17.56B). The position peaked in Q2 2025 at 172,800,851 shares, worth US$23.50B. Across 20 filings, Vanguard Group increased the stake 12 time(s), trimmed it 0 time(s) and left it unchanged 7 time(s). The most recent filing (Q4 2025) shows 175,556,716 shares valued at US$22.00B — an increase of 2,402,408 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2021 | 146.57M | $17.56B | New |
| Q2 2021 | 147.84M | $17.14B | Add |
| Q3 2021 | 148.78M | $17.58B | Add |
| Q4 2021 | 149.15M | $20.99B | Hold |
| Q1 2022 | 151.29M | $17.91B | Add |
| Q2 2022 | 152.55M | $16.57B | Add |
| Q3 2022 | 154.56M | $14.96B | Add |
| Q4 2022 | 155.48M | $17.07B | Add |
| Q1 2023 | 155.63M | $15.76B | Hold |
| Q2 2023 | 155.74M | $16.98B | Hold |
| Q3 2023 | 155.77M | $15.09B | Hold |
| Q4 2023 | 156.47M | $17.22B | Hold |
| Q1 2024 | 165.30M | $18.79B | Add |
| Q2 2024 | 166.35M | $17.29B | Add |
| Q3 2024 | 167.91M | $19.14B | Add |
| Q4 2024 | 168.65M | $19.08B | Hold |
| Q1 2025 | 169.82M | $22.53B | Add |
| Q2 2025 | 172.80M | $23.50B | Add |
| Q3 2025 | 173.15M | $23.19B | Hold |
| Q4 2025 | 175.56M | $22.00B | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 19 other funds we track also report a position in ABT — the largest reported positions include Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B), Sixth Street Partners Management Company, L.P. (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on Vanguard Group
FAQ
How long has Vanguard Group held ABT?
Vanguard Group has disclosed ABT holdings in 20 of the last 20 reported quarters, going back to Q1 2021.
What is Vanguard Group's current position in ABT?
As of Q4 2025, Vanguard Group holds 175.56M shares of ABT (ABBOTT LABORATORIES), valued at $22.00B, representing 0.32% of its reported portfolio and ranking #44.
Has Vanguard Group been buying or selling ABT?
In the latest 13F filing (Q4 2025), Vanguard Group increased its position in ABT. The position peaked in Q2 2025 at 172.80M shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, Sixth Street Partners Management Company, L.P., among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.